During the corresponding time, 10x Genomics Inc saw a revenue deteriorated by -12.23 % year on year, sequentially revenue grew by 0.57 %. While revenue at the 10x Genomics Inc 's corporate clients
10x Genomics Inc's Comment on Sales, Marketing and Customers
The company provides products to researchers worldwide, including academic, translational researchers, and biopharmaceutical companies. Their offerings enable high-resolution, large-scale analysis of biological systems, supporting research in oncology, immunology, and neuroscience. Since 2015, the company has sold 8,046 instruments globally. Their single cell portfolio, based on the Chromium platform, facilitates high-throughput analysis of individual biological components with applications such as gene expression, protein analysis, chromatin, V(D)J, CRISPR/gRNAs, and antigen analysis. This portfolio is compatible with various sample types and delivers high performance. Additionally, the company offers QuantumScale Single Cell RNA and Single Cell Methylation kits acquired through Scale Biosciences, Inc.
In a groundbreaking development, leading innovator in single cell and spatial biology, 10x Genomics, has announced the commercial availability of its highly anticipated Chromium GEM-X products. This next generation of their renowned single cell technology architecture promises to revolutionize the field by enhancing performance, scalability, and cost-effectiveness. With 10x Genomics commitment to advancing research capabilities, scientific communities worldwide eagerly anticipate the transformative potential of this cutting-edge solution. 10x Genomics Inc., a Nasdaq-listed company at the forefront of genomics technology, unveiled Chromium GEM-X amidst much excitement and anticipation. The GEM-X technology o...
10x Genomics Inc’s Comment on Sales, Marketing and Customers
The company provides products to researchers worldwide, including academic, translational researchers, and biopharmaceutical companies. Their offerings enable high-resolution, large-scale analysis of biological systems, supporting research in oncology, immunology, and neuroscience. Since 2015, the company has sold 8,046 instruments globally. Their single cell portfolio, based on the Chromium platform, facilitates high-throughput analysis of individual biological components with applications such as gene expression, protein analysis, chromatin, V(D)J, CRISPR/gRNAs, and antigen analysis. This portfolio is compatible with various sample types and delivers high performance. Additionally, the company offers QuantumScale Single Cell RNA and Single Cell Methylation kits acquired through Scale Biosciences, Inc.
Sources:
10x Genomics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: 10x Genomics Inc’s corporate clients.
For your research, we’ve provided 9 tables on 10x Genomics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
197.96 %